Endoscopic Radiofrequency Ablation Induced Tumor Microenvironment Remodeling In Cholangiocarcinoma

Overview

About this study

The objective of the study is to study the systemic immunological effects of Radiofrequency Ablation in patients with advanced Extrahepatic cholangiocarcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults over 18 years of age with an extrahepatic cholangiocarcinoma who are scheduled to undergo endoscopic retrograde cholangiopancreatography procedure as part of clinical care.
  • Subjects able to give appropriate consent to the study.

Exclusion Criteria:

  • History of prior RFA.
  • Refusal to consent. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/08/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Vinay Chandrasekhara, M.D.

Contact us for the latest status

Contact information:

Chinmay Guralwar

5072556866

guralwar.chinmay@mayo.edu

More information

Publications

Publications are currently not available